Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Verrica Pharmaceuticals Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
12
9.03
5.12
7.57
35.6
Cost of revenue
0.5
2.6
Gross profit
4.62
4.97
Research and development
3.73
12.8
15.4
15.7
15.9
12.2
20.3
11.8
8.86
Selling, general and administrative
17.4
47.3
58.8
35.2
General and administrative
0.73
9.05
14.6
24.5
27
17.4
Operating expenses
4.46
21.9
30.1
40.2
42.9
30.3
70.9
73.5
47.8
Operating income
-4.46
-21.9
-30.1
-40.2
-30.9
-21.3
-65.8
-65.9
-12.2
Interest expense
3.03
4.3
2.17
3.96
9.41
7.74
Interest income
1.23
1.88
0.52
0.12
0.48
2.74
1.42
0.93
Other non-operating income
-0
1.23
1.87
-2.51
-4.17
-3.19
-1.24
-10.7
-5.7
Income tax
0
0
0
0
Net income
-4.46
-20.6
-28.2
-42.7
-35.1
-24.5
-67
-76.6
-17.9
EBITDA
-21.9
-30
-40.1
-30.7
-20.8
-65.2
-65.6
-12.1
EPS, basic
-15.58
-14.08
-11.28
-17.08
-12.98
-7.19
-14.78
-14.78
-1.68
EPS, diluted
-15.58
-14.08
-11.28
-17.08
-12.98
-7.19
-14.78
-14.78
-1.68
Shares, basic (weighted)
0.29
1.47
2.49
2.5
2.71
3.42
4.54
5.18
10.7
Shares, diluted (weighted)
0.29
1.47
2.49
2.5
2.71
3.42
4.54
5.18
10.7
Balance sheet
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
8.66
10.3
9.24
10.7
15.8
34.3
69.5
46.3
30.1
Short-term investments
0
0
Receivables
0
4.25
0.05
5.26
Inventory
0
1.02
2.46
2.24
Other current assets
0.42
1.34
2.97
2.18
3.97
4.36
2.55
2.31
2.8
Total current assets
9.08
91.2
65
67.7
74.3
39.1
77.5
51.2
42.5
Property, plant and equipment
0.26
2.09
3.1
3.89
3.89
1.05
0.59
0.21
Lease right-of-use assets
0.11
1.84
1.61
1.44
1.16
0.84
0.54
Other non-current assets
1.24
1.57
0.3
0.28
0.45
0.38
0.38
Total assets
9.08
91.9
68.4
74.2
80.1
44.7
81.6
54.1
47.1
Accounts payable
0.15
0.92
1.19
0.35
0.85
0.51
2.46
1.9
2.07
Accrued liabilities
0.45
1.52
2.04
1.34
1.67
1.4
3.44
1.17
1.76
Deferred revenue
0.5
0
0.78
Short-term debt
35.3
41.7
0
0
12.9
0
Total current liabilities
0.62
2.48
3.35
39.5
46.1
3.46
17
29
16.4
Lease liabilities
0.06
1.69
1.45
1.23
0.91
0.58
0.24
Total liabilities
0.62
2.48
3.41
41.2
47.5
4.69
61.8
64
22.4
Total debt
0
42.9
31
0
Paid-in capital
5.39
123
127
137
172
203
250
297
350
Retained earnings
-12.4
-33.1
-61.2
-104
-139
-163
-230
-307
-325
Treasury stock
0
0
0
0
0
0
0
0
0
Other comprehensive income
-0.02
0.02
0
-0.03
0
Shareholders' equity
-7.04
89.4
65
33
32.6
40
19.8
-9.86
24.7
Total equity
-7.04
89.4
65
33
32.6
40
19.8
-9.86
24.7
Total liabilities and equity
9.08
91.9
68.4
74.2
80.1
44.7
81.6
54.1
47.1
Shares outstanding
0.37
2.57
2.58
2.55
2.76
4.11
4.25
9.18
17.2
Cash flow statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-4.46
-20.6
-28.2
-42.7
-35.1
-24.5
-67
-76.6
-17.9
Depreciation and amortization
0.02
0.06
0.04
0.24
0.45
0.53
0.34
0.13
Stock-based compensation
0.08
2.25
3.33
9.82
6.05
4.99
14.4
7.16
3.32
Deferred income tax
-2.4
-2.4
Change in receivables
0
-3.86
4.2
-5.21
Change in payables
0.09
0.77
0.26
-0.84
0.5
-0.34
2.2
-0.57
0.18
Cash from operations
-4.58
-17.9
-27.4
-30.2
-27.6
-18.7
-38.6
-60.9
-17.6
Capital expenditures
-0.77
-0.68
-1.47
-0.88
-0.3
-0.36
-0.03
0
Purchases of investments
-79.1
-89.9
-71.7
-68.9
-4.49
0
Sales and maturities of investments
118
69.8
69
59
0
Cash from investing
-79.9
26
-3.58
-1
54
-0.36
-0.02
0
Stock issued
0.01
0.42
0.45
28.1
26.9
0.01
0.16
0
Cash from financing
12.7
99.4
0.42
35.2
33.6
-16.9
74.2
37.7
1.45
Net change in cash
8.14
1.61
-1.03
1.45
5.07
18.5
35.3
-23.2
-16.2
Free cash flow
-18.6
-28.1
-31.7
-28.5
-19
-38.9
-61
-17.6
Interest paid
0
1.88
2.85
1.79
3.15
7.23
5.17
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.37 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-93.6%
Operating income / revenue.
EBITDA margin
-93.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-102.8%
Net income / revenue.
Operating cash flow margin
-44.0%
Cash from operations / revenue.
Return on equity (ROE)
-724.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-86.6%
Net income / average total assets.
R&D / revenue
48.2%
Research and development expense / revenue.
SG&A / revenue
124.9%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
11.6%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
0.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
370.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
57.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 3y
-14.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-5.6%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-12.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
1.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-8.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
105.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
46.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
33.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.45x
Current assets / current liabilities.
Quick ratio
0.99x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.50x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.42
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.63
Cash from operations / diluted weighted shares.
Book value per share
$0.25
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
2.48x
Market cap / revenue.
P/B
17.4x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
17.4x
Market cap / tangible book value, when positive.
EV/Sales
2.11x
Enterprise value / revenue.
Earnings yield
-41.5%
Net income / market cap (the inverse of P/E).
What was Verrica Pharmaceuticals Inc.'s revenue in fiscal 2025?
Verrica Pharmaceuticals Inc. reported revenue of $35.6M for fiscal 2025, 370.2% higher than the year before.
Was Verrica Pharmaceuticals Inc. profitable in fiscal 2025?
No. It reported a net loss of $17.9M.
How much free cash flow did Verrica Pharmaceuticals Inc. generate in fiscal 2025?
Cash from operations of $17.6M minus capital expenditures of $0.0 left free cash flow of -$17.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.